阴道孕酮预防宫颈缩短孕妇早产:2岁幼儿结局随访
本研究为Triple P试验的随访研究,纳入80例宫颈缩短(≤30 mm)且其他低危的孕妇,随机接受阴道孕酮(n=41)或安慰剂(n=39)。在矫正年龄2岁时对59/77(77%)儿童进行神经发育评估,孕酮组与安慰剂组BSID-III认知评分(101.6 vs 105.0)和运动评分(102.4 vs 107.3)均无显著差异,身体、行为和健康相关结局亦无差异。
要点
- 宫颈缩短低危孕妇产前暴露阴道孕酮,子代2岁时BSID-III认知和运动评分与安慰剂组无显著差异。
- 两组儿童在体格检查(含生殖器和神经系统)、行为及健康相关结局方面均未见差异。
- 孕酮组新生儿期死亡1例,安慰剂组2例;随访率59/77(77%)。
核心结论
- 在宫颈缩短的低危孕妇所生儿童样本中,产前暴露阴道孕酮与安慰剂相比,神经发育、行为、健康相关和身体结局均未发现相关差异。
研究设计与样本
- Triple P随机对照试验的随访研究,80例孕18-22周宫颈长度≤30 mm的低危孕妇随机接受孕酮(n=41)或安慰剂(n=39)。
- 在矫正年龄2岁时进行盲法神经发育评估(BSID-III)及神经和体格检查,家长填写年龄与发育进程问卷、儿童行为量表(CBCL)和一般健康问卷。
- 样本量由原Triple P试验决定,提供80%把握度检测BSID-III组间15分(1个标准差)的平均差异。
主要发现
- 孕酮组与安慰剂组平均BSID-III认知评分分别为101.6与105.0(平均差-3.4,95%CI -9.3至2.6;P=0.29)。
- 孕酮组与安慰剂组平均运动评分分别为102.4与107.3(平均差-4.9,95%CI -11.2至1.4;P=0.13)。
- 两组在体格检查(包括生殖器和神经系统检查)、行为及健康相关结局方面均未见差异。
- 随访儿童出生中位孕周为38+6周(四分位距37+3至40+1周),中位出生体重3240 g(四分位距2785-3620 g)。
- 孕酮组新生儿期死亡1例,安慰剂组2例;共获得59/77(77%)儿童的随访数据,57例有BSID-III结果(孕酮组n=28,安慰剂组n=29)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 样本量由原Triple P试验决定,提供80%把握度检测BSID-III组间15分(1个标准差)的平均差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the long-term outcomes of children born to women with a short cervix and otherwise low risk for preterm birth, after antenatal exposure to vaginal progesterone vs placebo. METHODS: This was a follow-up study of the Triple P trial, which randomized 80 low-risk women with a short cervix (≤ 30 mm) at 18-22 weeks' gestation to progesterone (n = 41) or placebo (n = 39). At 2 years of corrected age, children were invited for a neurodevelopmental assessment, using the Bayley Scales of Infant and Toddler Development, third edition (BSID-III), and a neurological and physical examination by an assessor blinded to the allocated treatment. Parents filled out the Ages and Stages Questionnaire, the Child Behavior Checklist (CBCL) and a general-health questionnaire. The main outcome of interest was mean BSID-III cognitive and motor scores. Additionally, a composite score of mortality and abnormal developmental outcome, including BSID-III ≤-1 SD, CBCL score in the clinical range and/or parental reported physical problems (at least two operations or at least two hospital admissions in the previous 2 years), was evaluated. Our sample size, dictated by the original sample of the Triple P trial, provided 80% power to detect a mean difference (MD) of 15 points (1 SD) between groups for the BSID-III tests. RESULTS: Of the 80 children born to the randomized women, one in the progesterone group and two in the placebo group died in the neonatal period. Follow-up data were obtained for 59/77 (77%) children and BSID-III outcomes in 57 children (n = 28 in the progesterone group and n = 29 in the placebo group) born at a median gestational age of 38 + 6 weeks (interquartile range (IQR), 37 + 3 to 40 + 1 weeks) with a median birth weight of 3240 g (IQR, 2785-3620 g). In the progesterone vs placebo groups, mean BSID-III cognitive development scores were 101.6 vs 105.0 (MD, -3.4 (95% CI, -9.3 to 2.6); P = 0.29) while mean motor scores were 102.4 vs 107.3 (MD, -4.9 (95% CI, -11.2 to 1.4); P = 0.13). No differences were seen between the two groups in physical (including genital and neurological examination), behavioral and health-related outcomes. CONCLUSION: In this sample of children born to low-risk women with a short cervix at screening, no relevant differences in neurodevelopmental, behavioral, health-related and physical outcomes were found between offspring exposed to vaginal progesterone and those exposed to placebo. © 2020 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Cuijpers CJJ, Van't Hooft J, Schneeberger C, et al. Progesterone for prevention of preterm birth in women with short cervical length: 2-year infant outcomes. Ultrasound Obstet Gynecol. 2021. PMID: 32959909. doi:10.1002/uog.23126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。